Financial GrowthBioMarin is focusing on high return on investment programs and improving business operations, which is expected to drive significant growth with Voxzogo potentially yielding peak sales of around $1.3 billion.
Operational EfficiencyManagement's focus on improving profitability by discontinuing four pipeline programs reflects a strategic approach to cost management, potentially yielding significant operational savings.
Product AdoptionVoxzogo's established efficacy/safety profile is a key differentiator against competitors, leading to strong adoption rates with 500 new patients, totaling 3,100 patients in treatment.